Overview
- The authorization represents the first global approval for an oral GLP-1 therapy, as reported following the FDA decision.
- Novo plans a U.S. launch in early January with availability at pharmacies and through select telehealth providers.
- The pill will debut with a 1.5 milligram starting dose, according to the company’s announcement.
- Novo Nordisk shares jumped roughly 8% to 10% intraday after the approval, placing the stock among the day’s top performers.
- The gains arrived on a session when major U.S. indexes edged lower, highlighting a company-specific move.